Clinical implications of KIT and PDGFRA genotyping in GIST
Clin. transl. oncol. (Print)
; 12(10): 670-676, oct. 2010. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-124356
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs are characterised by the expression of KIT, a type III tyrosine kinase receptor, and the presence of mutations in KIT or PDGFRA in about 80-85% of cases. The primary treatment for GIST is surgery, which cures most patients with low- or intermediate-risk tumours. The introduction of the kinase inhibitor imatinib mesylate, and sunitinib in second line, against KIT and PDGFRA has provided the first evidence of directed therapy in GIST. The aim of this review is to highlight the growing evidence that KIT and PDGFRA genotyping provides valuable information for the clinical management of GIST patients. We show that KIT and PDGFRA genotyping has emerged as one of the principal factors in the evaluation of GISTs, particularly in those tumours that are clearly malignant or have a high risk of recurrence. In addition to helping establish the diagnosis of GIST in unusual cases, genotyping can be very useful to physicians and patients in deciding on imatinib dose, in estimating the likelihood and duration of benefit, and potentially in selecting second-line therapies (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Proteínas Proto-Oncogênicas c-kit
/
Receptor alfa de Fator de Crescimento Derivado de Plaquetas
/
Tumores do Estroma Gastrointestinal
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
Fundación Instituto Valenciano de Oncología/Spain
/
Institut Universitari d´Investigacions en Ciencies de la Salut (IUNICS)/Spain
/
Son Dureta Hospital/Spain